- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | iSpecimen plans $200M Solana-based digital asset treasury | 2 | Seeking Alpha | ||
| Do | iSpecimen plans up to $200 million Solana-based treasury reserve | 3 | Investing.com | ||
| Do | iSpecimen Inc.: iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow | 358 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today... ► Artikel lesen | |
| Do | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.08. | iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market | 3 | GlobeNewswire (USA) | ||
| 31.07. | iSpecimen announces $1.75M at-the-market equity offering | 1 | Seeking Alpha | ||
| 31.07. | iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market | 2 | GlobeNewswire (USA) | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| 25.07. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07. | iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering | 2 | GlobeNewswire (USA) | ||
| 24.07. | iSpecimen-Aktie fällt nach Preisgestaltung für Kapitalerhöhung | 3 | Investing.com Deutsch | ||
| 24.07. | iSpecimen stock falls after pricing $4 million public offering | 1 | Investing.com | ||
| 24.07. | iSpecimen announces pricing of $4M underwritten offering | 1 | Seeking Alpha | ||
| 24.07. | iSpecimen prices $4 million public offering at $0.70 per share | 1 | Investing.com | ||
| 10.07. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 27.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 24.06. | iSpecimen gibt Änderungen im Vorstand und neue Direktorenernennung bekannt | 1 | Investing.com Deutsch | ||
| 24.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | iSpecimen Inc. - S-1/A, General form for registration of securities | 10 | SEC Filings | ||
| 05.06. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 83,77 | +2,53 % | Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit | ||
| CRISPR THERAPEUTICS | 48,800 | +2,09 % | CRISPR Therapeutics - CRSP: Short Squeeze bei der Schweizer Biotech-Aktie? | Short Float bei 29.37% Seit Jahren keine Gewinne bei CRISPR Therapeutics (CRSP). Insider kauft trotzdem! JETZT Pullback-Setup! CRISPR Therapeutics (CRSP) - ISIN CH0334081137 Rückblick: Die Kombination... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,562 | +3,26 % | Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus | ||
| EDITAS MEDICINE | 1,943 | +2,72 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 107,95 | +1,08 % | Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) announced a profit for its second quarter that Increased from the same period last year and beat the Street estimates.The company's bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,545 | -1,89 % | Arrowhead Pharma: Leerink Partners senkt Kursziel auf 21 US-Dollar | ||
| GALAPAGOS NV | 26,940 | -0,81 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,990 | -0,75 % | A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts | ||
| RECURSION PHARMACEUTICALS | 5,330 | +0,66 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| TWIST BIOSCIENCE | 23,950 | +0,63 % | JPMorgan senkt Kursziel für Twist Bioscience auf 25 US-Dollar | ||
| REPLIGEN | 101,00 | +4,77 % | REPLIGEN CORP - 10-Q, Quarterly Report | ||
| ROCKET PHARMACEUTICALS | 2,484 | -1,47 % | Rocket Pharmaceuticals: Jefferies hebt Kursziel an, bleibt aber bei "Hold" | ||
| XBIOTECH | 2,580 | +1,57 % | XBiotech beruft Thomas Kündig und Craig Rademaker in den Vorstand | ||
| SPERO THERAPEUTICS | 1,900 | +0,42 % | Earnings Outlook For Spero Therapeutics | ||
| PERSONALIS | 3,976 | +2,42 % | Personalis outlines $70M-$80M revenue target for 2025 amid 59% sequential clinical test growth and revised biopharma outlook |
ISPECIMEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,79 % bei einem Aktienkurs von 1,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.